Literature DB >> 33865949

Geographical socioeconomic disadvantage is associated with adverse outcomes following major amputation in diabetic patients.

George Q Zhang1, Joseph K Canner2, Ahmed Kayssi3, Christopher J Abularrage4, Caitlin W Hicks5.   

Abstract

OBJECTIVE: Socioeconomic disadvantage is a known predictor of adverse outcomes and amputation in patients with diabetes. However, its association with outcomes after major amputation has not been described. Here, we aimed to determine the association of geographic socioeconomic disadvantage with 30-day readmission and 1-year reamputation rates among patients with diabetes undergoing major amputation.
METHODS: Patients from the Maryland Health Services Cost Review Commission Database who underwent major lower extremity amputation with a concurrent diagnosis of diabetes mellitus between 2015 and 2017 were stratified by socioeconomic disadvantage as determined by the area deprivation index (ADI) (ADI1 [least deprived] to ADI4 [most deprived]). The primary outcomes were rates of 30-day readmission and 1-year reamputation, evaluated using multivariable logistic regression models and Kaplan-Meier survival analyses.
RESULTS: A total of 910 patients were evaluated (66.0% male, 49.2% Black), including 30.9% ADI1 (least deprived), 28.6% ADI2, 19.1% ADI3, and 21.2% ADI4 (most deprived). After adjusting for differences in baseline demographic and clinical factors, the odds of 30-day readmission was similar among ADI groups (P > .05 for all). Independent predictors of 30-day readmission included female sex (odds ratio [OR], 1.45), Medicare insurance (vs private insurance; OR, 1.76), and peripheral artery disease (OR, 1.49) (P < .05 for all). The odds of 1-year reamputation was significantly greater among ADI4 (vs ADI1; OR, 1.74), those with a readmission for stump complication or infection/sepsis (OR, 2.65), and those with CHF (OR, 1.53) or PAD (OR, 1.59) (P < .05 for all).
CONCLUSIONS: Geographic socioeconomic disadvantage is independently associated with 1-year reamputation, but not 30-day readmission, among Maryland patients undergoing a major amputation for diabetes. A directed approach at improving postoperative management of chronic disease progression in socioeconomically deprived patients may be beneficial to reducing long-term morbidity in this high-risk group.
Copyright © 2021 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Area deprivation index; Diabetes; Major amputation; Readmission; Reamputation

Mesh:

Year:  2021        PMID: 33865949      PMCID: PMC8487910          DOI: 10.1016/j.jvs.2021.03.033

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.860


  42 in total

1.  Do multidisciplinary care plans result in better care for patients with type 2 diabetes?

Authors:  Nicholas A Zwar; Oshana Hermiz; Elizabeth J Comino; Timothy Shortus; Joan Burns; Mark Harris
Journal:  Aust Fam Physician       Date:  2007 Jan-Feb

2.  Re-amputations and mortality after below-knee, through-knee and above-knee amputations.

Authors:  Morten T Schmiegelow; Nikolaj Sode; Troels Riis; Jes Bruun Lauritzen; Benn R Duus; Martin Lindberg-Larsen
Journal:  Dan Med J       Date:  2018-12       Impact factor: 1.240

3.  Measures of social deprivation that predict health care access and need within a rational area of primary care service delivery.

Authors:  Danielle C Butler; Stephen Petterson; Robert L Phillips; Andrew W Bazemore
Journal:  Health Serv Res       Date:  2012-07-20       Impact factor: 3.402

4.  Breast cancer screening, area deprivation, and later-stage breast cancer in Appalachia: does geography matter?

Authors:  Roger T Anderson; Tse-Chang Yang; Stephen A Matthews; Fabian Camacho; Teresa Kern; Heath B Mackley; Gretchen Kimmick; Christopher Louis; Eugene Lengerich; Nengliang Yao
Journal:  Health Serv Res       Date:  2013-09-30       Impact factor: 3.402

5.  Maryland's all-payer approach to delivery-system reform.

Authors:  Rahul Rajkumar; Ankit Patel; Karen Murphy; John M Colmers; Jonathan D Blum; Patrick H Conway; Joshua M Sharfstein
Journal:  N Engl J Med       Date:  2014-01-10       Impact factor: 91.245

6.  Risk of reamputation in diabetic patients stratified by limb and level of amputation: a 10-year observation.

Authors:  Yuki Izumi; Kathleen Satterfield; Shuko Lee; Lawrence B Harkless
Journal:  Diabetes Care       Date:  2006-03       Impact factor: 19.112

7.  Neighborhood socioeconomic disadvantage is not associated with wound healing in diabetic foot ulcer patients treated in a multidisciplinary setting.

Authors:  Caitlin W Hicks; Joseph K Canner; Nestoras Mathioudakis; Ronald L Sherman; Kathryn Hines; Christopher Lippincott; James H Black; Christopher J Abularrage
Journal:  J Surg Res       Date:  2017-12-22       Impact factor: 2.192

8.  Risk Factors for In-hospital Mortality and Reamputation Following Lower Limb Amputation.

Authors:  Sachiko Endoh; Hayato Yamana; Yasuo Nakahara; Hiroki Matsui; Kiyohide Fushimi; Hideo Yasunaga; Nobuhiko Haga
Journal:  Prog Rehabil Med       Date:  2017-12-26

9.  Diabetic foot disorders. A clinical practice guideline (2006 revision).

Authors:  Robert G Frykberg; Thomas Zgonis; David G Armstrong; Vickie R Driver; John M Giurini; Steven R Kravitz; Adam S Landsman; Lawrence A Lavery; J Christopher Moore; John M Schuberth; Dane K Wukich; Charles Andersen; John V Vanore
Journal:  J Foot Ankle Surg       Date:  2006 Sep-Oct       Impact factor: 1.286

10.  Community Deprivation Index and Discharge Destination After Elective Hip Replacement.

Authors:  Bella Mehta; Susan Goodman; Kaylee Ho; Michael Parks; Said A Ibrahim
Journal:  Arthritis Care Res (Hoboken)       Date:  2021-04       Impact factor: 4.794

View more
  1 in total

1.  New Diabetic Medication Sodium-Glucose Cotransporter-2 Inhibitors Can Induce Euglycemic Ketoacidosis and Mimic Surgical Diseases: A Case Report and Review of Literature.

Authors:  Antonia-Therese Kietaibl; Peter Fasching; Karl Glaser; Alexander H Petter-Puchner
Journal:  Front Surg       Date:  2022-03-24
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.